Beta netrin and uses thereof
AssigneesThe General Hospital Corporation, Tufts University
InventorsPamela Olson, Dale Hunter, William Brunken, Manuel Koch, Robert Burgeson
Life of this patent
Estimating the term…
Abstract
β-netrin nucleic acid molecules and polypeptides are provided. Methods of using the β-netrin nucleic acid molecules and polypeptides are also provided.
Claims31
A substantially pure nucleic acid comprising a nucleotide sequence which is at least 60% identical to the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:4.
A substantially pure nucleic acid which encodes a fragment of a beta-netrin peptide of at least 50 amino acids in length.
A substantially pure polypeptide which comprises at least 60% sequence identity to a beta-netrin polypeptide.
A substantially pure beta-netrin polypeptide which is encoded by a nucleic acid having at least 85% sequence identity with the nucleic acid of SEQ ID NO:
- 1, SEQ ID NO:3, or SEQ ID NO:5.
A purified preparation of an anti-beta-netrin antibody.
An immunogen comprising a Beta-netrin polypeptide in an immunogenic preparation, the immunogen being capable of eliciting an immune response specific for the Beta-netrin polypeptide.
A transgenic Beta-netrin animal.
A method of modulating neuronal development, the method comprising contacting a neuron with a sufficient amount of a Beta-netrin molecule to induce neuron outgrowth, guidance, or stability, thereby modulating neuronal development.
A method of modulating vascular development in a tissue, comprising contacting the tissue with a beta netrin molecule or a compound sufficient to modulate beta-netrin expression in the tissue, thereby modulating vascular development in a tissue.
A method of modulating kidney, ovary, heart, or muscle development, the method comprising contacting a kidney, ovary, heart, or muscle cell or tissue with a Beta-netrin molecule, thereby modulating kidney, ovary, heart, or muscle development.
A method of treating or preventing in a subject a Beta-netrin-related disorder, the method comprising administering to the subject an effective amount of beta-netrin molecule effective to treat or prevent the beta-netrin-related disorder in the subject.
A method of determining if a subject is at risk for a disorder related to a lesion in or the misexpression of a gene which encodes a Beta-netrin polypeptide comprising detecting, in a tissue of the subject, the presence or absence of a mutation which affects the expression of the Beta-netrin gene.
A method of evaluating a compound for the ability to interact with a subject Beta-netrin polypeptide comprising contacting the compound with the subject Beta-netrin polypeptide;
- and evaluating ability of the compound to interact with the subject Beta-netrin polypeptide.
A method of evaluating a compound for the ability to bind a nucleic acid encoding a subject Beta-netrin polypeptide, the method comprises contacting the compound with the nucleic acid and evaluating ability of the compound to form a complex with the nucleic acid.
Dependencies are inferred from the claim text.